MedTrace Logo

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)

NCT01855100 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2017-01-18

No results posted yet for this study

Summary

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Conditions

  • Venous Thrombosis

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • Belgium

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01855100 on ClinicalTrials.gov